NADPH Oxidase Inhibition Alleviates Diabetes‐Induced Myocardial Contractile Dysfunction

Nathan Roe,Paul Thomas,Jun Ren
DOI: https://doi.org/10.1096/fasebj.24.1_supplement.597.4
2010-01-01
Abstract:Reactive oxygen species are implicated in cardiac dysfunction in a variety of diseases including diabetes. Upregulation of the pro‐ROS enzyme NADPH oxidase (NOX) has been shown in diabetes and contributes to diabetic cardiac dysfunction. This study was designed to evaluate the effect of NADPH oxidase inhibitor apocynin on STZ–induced diabetic cardiac dysfunction. Experimental diabetes was induced in male C57 mice using STZ (150mg/kg) injection prior to administration of apocynin (4mg/kg/d for 2 wks in drinking water). Myocardial function was evaluated by echocardiography and edge‐detection. STZ treatment reduced fractional shortening, peak shortening, shortening/relengthening velocities, and systolic duration, all of which were attenuated or ablated by apocynin. There was no significant difference in systolic, diastolic or mean blood pressure among all groups tested. Apocynin treatment did not reverse the STZ‐induced loss in body weight or hyperglycemia. Western blot analysis revealed that apocynin failed to affect phosphorylation of the downstream insulin effector Akt, and dephosphorylation of AMPK. Apocynin did not affect STZ‐induced decrease in posterior wall thickness, suggesting a beneficial effect independent of cardiac remodeling. Taken together, our data indicated that inhibition of NADPH oxidase rescues diabetes‐induced myocardial dysfunction.
What problem does this paper attempt to address?